natgillin/translations-raw huggingface dataset:
NovoMix 70 FlexPen 100 units/ml suspension for injection in a pre-filled pen
NovoMix 70 FlexPen 100 jedinica/ml suspenzija za injekciju u napunjenoj brizgalici
NovoMix 70 FlexPen 100 units/ml suspension for injection in pre-filled pen
NovoMix 70 FlexPen 100 jedinica/ml suspenzija za injekciju u napunjenoj brizgalici
NovoMix 70 FlexPen Glass ball
NovoMix 70 FlexPen Staklena
NovoMix 70 FlexPen is a pre-filled pen designed to be used with NovoFine or NovoTwist needles.
NovoMix 70 FlexPen je napunjena brizgalica namijenjena uporabi s iglama NovoFine ili NovoTwist.
NovoMix 70 FlexPen is a pre-filled, colour-coded, disposable pen containing a mixture of rapid- acting and intermediate-acting insulin aspart in the ratio 70/30.
NovoMix 70 FlexPen je jednokratna napunjena brizgalica označena bojom koja sadrži mješavinu brzodjelujućeg i srednjedugodjelujućeg aspart inzulina u omjeru 70/30.
NovoMix 70 FlexPen is colour-coded and accompanied by a package leaflet with detailed instructions for use to be followed.
NovoMix 70 FlexPen označen je bojom i uz njega je priložena Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
NovoMix 70 is a modern insulin (insulin analogue) with both a rapid-acting and an intermediate- acting effect, in the ratio 70/30.
NovoMix 70 je moderni inzulin (inzulinski analog) s brzodjelujućim i srednjedugodjelujućim učinkom, u omjeru 70/30.
NovoMix 70 is essentially ‘sodium-free’.
NovoMix 70 sadrži zanemarive količine natrija.
NovoMix 70 may fully or partially meet this requirement.
NovoMix 70 može u potpunosti ili djelomično nadoknaditi tu potrebu.
NovoMix 70 must not be administered intravenously, as it may result in severe hypoglycaemia.
NovoMix 70 se ne smije primjenjivati intravenski jer to može rezultirati teškom hipoglikemijom.
NovoMix 70 Penfill 100 units/ml Suspension for injection
NovoMix 70 Penfill 100 jedinica/ml Suspenzija za injekciju
NovoMix 70 Penfill 100 units/ml suspension for injection in a cartridge
NovoMix 70 Penfill 100 jedinica/ml suspenzija za injekciju u ulošku
NovoMix 70 Penfill 100 units/ml suspension for injection in cartridge
NovoMix 70 Penfill 100 jedinica/ml suspenzija za injekciju u ulošku
NovoMix 70 Penfill is accompanied by a package leaflet with detailed instructions for use to be followed.
Uz NovoMix 70 Penfill priložena je Uputa o lijeku s detaljnim naputcima za primjenu koje valja slijediti.
NovoMix 70 will start to lower your blood sugar 10–20 minutes after you inject it, the maximum effect occurs between 1 and 4 hours after the injection, and the effect lasts for up to 14–24 hours.
NovoMix 70 počinje snižavati razinu šećera u krvi 10–20 minuta nakon što ga injicirate, maksimalan učinak postiže se između 1 i 4 sata nakon injiciranja, a učinak traje do 14–24 sata.
NovoNorm 0.5 mg tablets
NovoNorm 0,5 mg tablete
NovoNorm 0.5 mg tablets Repaglinide
NovoNorm 0,5 mg tablete repaglinid
NovoNorm 1 mg tablets
NovoNorm 1 mg tablete
NovoNorm 1 mg tablets Repaglinide
NovoNorm 1 mg tablete repaglinid
NovoNorm 2 mg tablets
NovoNorm 2 mg tablete
NovoNorm 2 mg tablets Repaglinide
NovoNorm 2 mg tablete repaglinid
NovoRapid 100 units/ml solution for injection Insulin aspart
NovoRapid 100 jedinica/ml otopina za injekciju aspart inzulin
NovoRapid contains less than 1 mmol sodium (23 mg) per dose, i.e.
NovoRapid sadrži manje od 1 mmol (23 mg) natrija po dozi tj.
NovoRapid FlexPen is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
NovoRapid FlexPen je napunjena brizgalica (označena bojom) namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm.
NovoRapid FlexPen is a pre-filled, colour–coded, disposable pen containing insulin aspart.
NovoRapid FlexPen je jednokratna napunjena brizgalica označena bojom koja sadrži aspart inzulin.
NovoRapid FlexTouch is a pre-filled pen (colour-coded) designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
NovoRapid FlexTouch je napunjena brizgalica (označena bojom) namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm.
NovoRapid FlexTouch is a pre-filled, colour–coded, disposable pen containing insulin aspart.
NovoRapid FlexTouch je jednokratna napunjena brizgalica označena bojom koja sadrži aspart inzulin.
NovoRapid InnoLet is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm.
NovoRapid InnoLet je napunjena brizgalica namijenjena uporabi s jednokratnim iglama NovoFine ili NovoTwist duljine do 8 mm.
NovoRapid insulin aspart
NovoRapid aspart inzulin
NovoRapid is a modern insulin (insulin analogue) with a rapid–acting effect.
NovoRapid je moderni inzulin (inzulinski analog) s brzodjelujućim učinkom.
NovoRapid is a rapid–acting insulin analogue.
NovoRapid je brzodjelujući inzulinski analog.
NovoRapid is essentially ‘sodium–free’.
NovoRapid sadrži zanemarive količine natrija.
NovoRapid may be used for CSII in pump systems suitable for insulin infusion.
NovoRapid se može koristiti za KSII uz pomoć pumpe pogodne za inzulinsku infuziju.
NovoRapid may be used in an infusion pump system (CSII) as described in section 4.2. Tubings in which the inner surface materials are made of polyethylene or polyolefin have been evaluated and found compatible with pump use.
NovoRapid se može primijeniti uz pomoć infuzijske pumpe (KSII), kako je opisano u dijelu 4.2. Ispitani su kateteri čija je unutarnja stijenka načinjena od polietilena ili poliolefina te je utvrđeno da su kompatibilni s pumpama.
NovoRapid Penfill and FlexPen:
NovoRapid Penfill i FlexPen:
NovoRapid PumpCart contains 1.6 ml insulin aspart solution, equivalent to 160 units.
NovoRapid PumpCart sadrži 1,6 ml otopine aspart inzulina, što odgovara 160 jedinica.
NovoRapid PumpCart is for injection under the skin (subcutaneously) via a pump.
NovoRapid PumpCart je namijenjen injiciranju pod kožu (supkutano) uz pomoć pumpe.
NovoRapid PumpCart is ready for use directly in the pump.
NovoRapid PumpCart spreman je za izravnu primjenu u inzulinskoj pumpi.
NovoRapid PumpCart must be protected from excessive heat and light during storage and use.
NovoRapid PumpCart mora biti zaštićen od prekomjerne topline i svjetlosti tijekom čuvanja i uporabe.
NovoRapid PumpCart should be kept out of reach of others, especially children.
NovoRapid PumpCart treba čuvati izvan dohvata drugih osoba, osobito djece.
NovoRapid Vial, InnoLet, FlexTouch and PumpCart:
NovoRapid bočica, InnoLet, FlexTouch i PumpCart:
NovoRapid vial/NovoRapid Penfill
NovoRapid bočica/NovoRapid Penfill
NovoRapid vials are for use with insulin syringes with the corresponding unit scale.
NovoRapid bočice koriste se s inzulinskim štrcaljkama s odgovarajućom jediničnom skalom.
NovoRapid will start to lower your blood sugar 10–20 minutes after you inject it, a maximum effect occurs between 1 and 3 hours after the injection and the effect lasts for 3–5 hours.
NovoRapid počinje snižavati razinu šećera u krvi 10-20 minuta nakon što ga injicirate, maksimalan učinak postiže se između 1 i 3 sata nakon injiciranja, a učinak traje 3-5 sati.
NovoSeven 1 mg (50 KIU) powder and solvent for solution for injection
NovoSeven 1 mg (50 KIU) prašak i otapalo za otopinu za injekciju
NovoSeven 1 mg Powder for injection Eptacog alfa (activated) IV
NovoSeven 1 mg Prašak za injekciju eptakog alfa (aktivirani) i.v.
NovoSeven 2 mg (100 KIU) powder and solvent for solution for injection
NovoSeven 2 mg (100 KIU) prašak i otapalo za otopinu za injekciju
NovoSeven 2 mg Powder for injection Eptacog alfa (activated) IV
NovoSeven 2 mg Prašak za injekciju eptakog alfa (aktivirani) i.v.
NovoSeven 5 mg (250 KIU) powder and solvent for solution for injection
NovoSeven 5 mg (250 KIU) prašak i otapalo za otopinu za injekciju
NovoSeven 5 mg Powder for injection Eptacog alfa (activated) IV
NovoSeven 5 mg Prašak za injekciju eptakog alfa (aktivirani) i.v.
NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection
NovoSeven 8 mg (400 KIU) prašak i otapalo za otopinu za injekciju
NovoSeven 8 mg Powder for injection Eptacog alfa (activated) IV
NovoSeven 8 mg Prašak za injekciju eptakog alfa (aktivirani) i.v.
NovoSeven can also be used to replace the missing factor VII in patients with factor VII deficiency.
NovoSeven se također može upotrebljavati kao zamjena za faktor VII u bolesnika s nedostatkom faktora VII.
NovoSeven contains sucrose
NovoSeven sadrži saharozu
NovoSeven contains the sugar sucrose which consists of fructose and glucose.
NovoSeven sadrži šećer saharozu koji se sastoji od fruktoze i glukoze.
NovoSeven eptacog alfa
NovoSeven eptakog alfa
NovoSeven has also been studied in patients with Glanzmann’s thrombasthenia who could not be treated with platelets.
NovoSeven je također ispitivan u bolesnika s Glanzmannovom trombastenijom koji nisu mogli biti liječeni trombocitima.
NovoSeven is a powder and solvent that are made up into a solution for injection.
NovoSeven je prašak i otapalo od kojih se priprema otopina za injekciju.
NovoSeven is given by injection into a vein.
NovoSeven se daje injekcijom u venu.
NovoSeven is presented as powder and solvent for solution for injection containing 1 mg eptacog alfa (activated) per vial (corresponds to 50 KIU/vial).
NovoSeven se sastoji od praška i otapala za otopinu za injekciju i sadrži 1 mg eptakoga alfa (aktiviranog) po bočici (što odgovara 50 KIU/bočici).
NovoSeven is presented as powder and solvent for solution for injection containing 2 mg eptacog alfa (activated) per vial (corresponds to 100 KIU/vial).
NovoSeven se sastoji od praška i otapala za otopinu za injekciju i sadrži 2 mg eptakoga alfa (aktiviranog) po bočici (što odgovara 100 KIU/bočici).
NovoSeven is presented as powder and solvent for solution for injection containing 5 mg eptacog alfa (activated) per vial (corresponds to 250 KIU/vial).
NovoSeven se sastoji od praška i otapala za otopinu za injekciju i sadrži 5 mg eptakoga alfa (aktiviranog) po bočici (što odgovara 250 KIU/bočici).
NovoSeven is presented as powder and solvent for solution for injection containing 8 mg eptacog alfa (activated) per vial (corresponds to 400 KIU/vial).
NovoSeven se sastoji od praška i otapala za otopinu za injekciju i sadrži 8 mg eptakoga alfa (aktiviranog) po bočici (što odgovara 400 KIU/bočici).
NovoSeven is used for the treatment and prevention of bleeding connected with surgery in the following groups of patients: patients with congenital haemophilia (a bleeding disorder present from birth) who have developed or are expected to develop ‘inhibitors’ (antibodies) against factor VIII or IX; patients with acquired haemophilia (a disease caused by the spontaneous development of inhibitors to factor VIII); patients with congenital factor VII deficiency;
NovoSeven se koristi za liječenje i prevenciju krvarenja kod operativnih zahvata u sljedećih skupina bolesnika: u bolesnika s prirođenom hemofilijom (poremećaj krvarenja prisutan od rođenja) koji su razvili ili za koje se očekuje da će razviti „inhibitore” (protutijela) na faktore VIII ili IX; u bolesnika sa stečenom hemofilijom (bolest koju prouzročuje spontani razvoj inhibitora na faktor VIII); u bolesnika s prirođenim nedostatkom faktora VII;
NovoSeven powder and solvent vials should be at room temperature at reconstitution.
Bočice s NovoSeven praškom i otapalom prilikom rekonstitucije trebaju biti na sobnoj temperaturi.
NovoSeven reconstituted solution is colourless and should be inspected visually for particulate matter and discolouration prior to administration.
Rekonstituirana otopina lijeka NovoSeven bezbojna je i treba je prije primjene vizualno pregledati na prisutnost čestica ili promjenu boje.
NovoThirteen (A-subunit) binds to free human FXIII B-subunit resulting in a heterotetramer [rA2B2] with a similar half-life to endogenous [A2B2].
NovoThirteen (A-podjedinica) veže se na slobodni humani FXIII B-podjedinicu stvarajući heterotetramer [rA2B2] s poluvijekom sličnim endogenom [A2B2].
NovoThirteen 2500 IU powder and solvent for solution for injection
NovoThirteen 2500 IU prašak i otapalo za otopinu za injekciju
NovoThirteen 2500 IU powder and solvent for solution for injection catridecacog (rDNA factor XIII)
NovoThirteen 2500 IU prašak i otapalo za otopinu za injekciju katridekakog (rDNK faktor XIII)
NovoThirteen 2500 IU powder for injection catridecacog
NovoThirteen 2500 IU prašak za injekciju katridekakog
NovoThirteen can be used in children and adolescents in the same way as in adults.
NovoThirteen se u djece i adolescenata može primjenjivati na isti način kao i u odraslih.
NovoThirteen contains sodium
NovoThirteen sadrži natrij
NovoThirteen contains the active substance catridecacog, which is identical to human coagulation factor XIII, an enzyme necessary for blood clotting.
NovoThirteen sadrži djelatnu tvar katridekakog, koji je istovjetan humanom koagulacijskom faktoru XIII, enzimu neophodnom za zgrušavanje krvi.
NovoThirteen has no influence on the ability to drive and use machines.
NovoThirteen ne utječe na sposobnost upravljanja vozilima i rada sa strojevima.
NovoThirteen is a recombinant coagulation factor XIII A-subunit produced in yeast cells (Saccharomyces cerevisiae) by recombinant DNA technology.
NovoThirteen je rekombinantni koagulacijski faktor XIII A-podjedinica proizveden u stanicama kvasca (Saccharomyces cerevisiae) tehnologijom rekombinantne DNK.
NovoThirteen is supplied as a powder and solvent for solution for injection (2500 IU powder in a vial and 3.2 ml solvent in a vial, with a vial adapter).
NovoThirteen dolazi u obliku praška i otapala za otopinu za injekciju (2500 IU praška u bočici i 3,2 ml otapala u bočici, s nastavkom za bočicu).
NovoThirteen is used for the long-term prevention of bleeding in patients with a condition called ‘congenital factor XIII A-subunit deficiency’.
NovoThirteen se koristi za dugoročnu prevenciju krvarenja u bolesnika sa stanjem naziva „nedostatak faktora XIII podjedinice A”.
NovoThirteen is used to prevent bleeding in patients who do not have enough factor XIII.
NovoThirteen se koristi za sprječavanje krvarenja u bolesnika koji nemaju dovoljno faktora XIII.
NovoThirteen was investigated in a main study involving 41 adults and children above 6 years of age with congenital factor XIII A-subunit deficiency who had been treated in the past with medicines containing factor XIII.
NovoThirteen je ispitan u jednom glavnom ispitivanju koje je obuhvatilo 41 odraslu osobu i djecu stariju od 6 godina s prirođenim nedostatkom faktora XIII podjedinice A koji su prethodno liječeni lijekovima koji su sadržavali faktor XIII.
Now choose the place on your body where you are going to give yourself the injection.
Sada odaberite mjesto na tijelu gdje ćete si dati injekciju.
NOW DIALS UP TO 80 units
SADA SE MOŽE ODMJERITI DO 80 jedinica
Now pull off the plastic needle cover.
Sada možete povući zaštitni pokrov s igle.
Now put the pen cap back onto the pen.
Sada vratite poklopac na brizgalicu.
Now remove and discard the adapter housing (E).
Sada skinite kućište s nastavka za bočicu i bacite ga (E).
Now screw the injection needle onto the pen securely by turning it in a clockwise direction (see Diagram F).
Sada pričvrstite iglu za injekciju na navoje brizgalice tako što ćete je pažljivo okretati u smjeru kazaljke na satu (vidjeti Dijagram F).
Now take the syringe between index and middle finger in the upward position
Sada primite štrcaljku između kažiprsta i srednjeg prsta držeći je i dalje u uspravnom položaju.
Now that the solution has been transferred into the syringe, firmly hold on to the barrel of the syringe (keeping the syringe plunger facing down) and disconnect the transparent Mix2Vial adapter from the syringe by unscrewing counterclockwise.
Kad je otopina prenesena u štrcaljku čvrsto uhvatite tijelo štrcaljke (dok je klip štrcaljke okrenut prema dolje) i odspojite prozirni nastavak Mix2Vial od štrcaljke odvijanjem u smjeru suprotnom od kazaljke na satu.
Now that the solution has been transferred into the syringe, firmly hold on to the barrel of the syringe (keeping the syringe plunger facing down) and disconnect the transparent Mix2Vial adapter from the syringe by unscrewing counterclockwise.
Kad je otopina prenesena u štrcaljku čvrsto uhvatite tijelo štrcaljke (dok je klip štrcaljke prema dolje) i odspojite prozirni nastavak Mix2Vial od štrcaljke odvijanjem u smjeru suprotnom od kazaljke na satu.
Now that the solution has been transferred into the syringe, firmly hold on to the barrel of the syringe (keeping the syringe plunger facing down) and disconnect the transparent Mix2Vial adapter from the syringe by unscrewing counterclockwise.
Kad je otopina prenesena u štrcaljku čvrsto uhvatite tijelo štrcaljke (dok je klip štrcaljke prema dolje) i odspojite prozirni nastavak Mix2Vial od štrcaljke odvijanjem u smjeru suprotnom od kazaljke na satu..
Now that the solution has been transferred into the syringe, firmly hold on to the barrel of the syringe (keeping the syringe plunger facing down) and disconnect the transparent Mix2Vial adapter from the syringe by unscrewing counterclockwise.
Kada je otopina prenesena u štrcaljku, čvrsto primite cilindar štrcaljke (s klipom okrenutim prema dolje) te odvojite prozirni adapter uređaja Mix2Vial od štrcaljke odvijanjem u smjeru suprotnom od kazaljke na satu.
Now that you have done the New Pen Setup, follow Section 3 for all of your injections.
Sada kada ste dovršili podešavanje nove brizgalice, slijedite upute u Dijelu 3 za svaku injekciju.
Now the patient breathes gently through the straw into the breath bag.
Bolesnik treba lagano izdisati kroz slamčicu u vrećicu za izdahnuti zrak.
Now the patient breathes gently through the straw into the breath sample container.
Bolesnik polako izdiše kroz slamčicu u spremnik za uzorak izdahnutog zraka.
Now the patient breathes gently through the straw into the breath sample container.
Bolesnik treba lagano izdisati kroz slamčicu u spremnik za uzorak izdahnutog zraka.
Now the patient breathes gently through the straw into the sample tube until the inside of the sample tube steams up.
Bolesnik treba lagano izdisati kroz slamčicu sve dok se unutrašnjost epruvete za uzimanje uzoraka ne zamagli.
Now the patient breathes gently through the straw until the inner surface of the sample tube steams up.
Bolesnik polako izdiše kroz slamčicu sve dok se unutarnja površina epruvete za uzimanje uzoraka ne zamagli.
Now the patient breathes gently through the straw.
Bolesnik polako izdiše kroz slamčicu.
Now the preparation of the test solution follows:
Potom slijedi pripremanje otopine za testiranje.
Now the second breath sample container (labelled “sampling time: 00-minute-value”) has to be filled up with breath in the same way as described above.
Zatim se izdahnutim zrakom mora napuniti i drugi spremnik za uzorak izdahnutog zraka (također označen naljepnicom „Vrijeme uzorkovanja: 00-minutna vrijednost“) na isti način kao i prvi.
Now the second sample container (labelled “sampling time: 00-minute-value”) has to be filled up with breath in the same way as described above.
Zatim se izdahnutim zrakom mora napuniti i drugi spremnik za uzorak (također označen naljepnicom „Vrijeme uzorkovanja: 00-minutna vrijednost“) na isti način kao i prvi.
Now turn over for information on how to use your NovoRapid PumpCart.
Okrenite stranicu radi informacija o uporabi uloška NovoRapid PumpCart.
Now turn over 
Okrenite stranicu 
Now turn over>
Sada okrenite>
Now you can slowly squirt HEMANGIOL from the syringe directly into your baby’s mouth.
Sada možete polako štrcati HEMANGIOL iz štrcaljke izravno u djetetova usta.
Now, gently turn the vial upside down and back
Sada lagano deset puta okrenite bočicu naopako i
Now, with the capsule locked in place, continue pushing the piston as far as it will go and then release.
Sada, s kapsulom blokiranom u mjestu, nastavite pritiskati klip koliko god ide i zatim ga otpustite.
Noxafil can also be used to prevent fungal infections in adults who are at high risk of getting a fungal infection, such as: patients who have a weak immune system due to having chemotherapy for “acute myelogenous leukemia” (AML) or “myelodysplastic syndromes” (MDS) patients having “high-dose immunosuppressive therapy” after “hematopoietic stem cell transplant” (HSCT).
Noxafil se također može primjenjivati za sprječavanje gljivičnih infekcija u odraslih s visokim rizikom od dobivanja gljivične infekcije, kao što su: bolesnici čiji je imunološki sustav oslabljen zbog kemoterapije koju primaju za liječenje akutne mijeloične leukemije (AML) ili mijelodisplastičnog sindroma (MDS) bolesnici koji primaju visoke doze imunosupresiva nakon transplantacije hematopoetskih matičnih stanica (HSCT).
Noxafil can be used in adults to treat the following types of fungal infections when other antifungal medicines have not worked or you have had to stop taking them: infections caused by fungi of the Aspergillus family that have not improved during treatment with the anti-fungal medicines amphotericin B or itraconazole or when these medicines have had to be stopped; infections caused by fungi of the Fusarium family that have not improved during treatment with amphotericin B or when amphotericin B has had to be stopped;
Noxafil se može primjenjivati za liječenje sljedećih vrsta gljivičnih infekcija u odraslih kada drugi antimikotici nisu djelovali ili ste ih morali prestati uzimati: infekcija prouzročenih gljivicama iz roda Aspergillus koje se nisu poboljšale tijekom liječenja antimikoticima amfotericinom B ili itrakonazolom ili kada se liječenje tim lijekovima moralo prekinuti; infekcija prouzročenih gljivicama iz roda Fusarium koje se nisu poboljšale tijekom liječenja amfotericinom B ili kada se liječenje amfotericinom B moralo prekinuti;
Noxafil can be used in adults to treat the following types of fungal infections when other antifungal medicines have not worked or you have had to stop taking them: infections caused by fungi of the Aspergillus family that have not improved during treatment with the anti-fungal medicines amphotericin B or itraconazole or when these medicines have had to be stopped; infections caused by fungi of the Fusarium family that have not improved during treatment with amphotericin B or when amphotericin B has had to be stopped;
Noxafil se može primjenjivati za liječenje sljedećih vrsta gljivičnih infekcija u odraslih kada drugi antimikotici nisu djelovali ili ste ih morali prestati uzimati: infekcija prouzročenih gljivicama iz roda Aspergillus koje se nisu poboljšale tijekom liječenja antimikoticima amfotericinom B ili itrakonazolom, ili kada se liječenje tim lijekovima moralo prekinuti; infekcija prouzročenih gljivicama iz roda Fusarium koje se nisu poboljšale tijekom liječenja amfotericinom B, ili kada se liječenje amfotericinom B moralo prekinuti;
Noxafil can increase the amount of these medicines in the blood which may lead to very serious changes to your heart rhythm: any medicines that contain “ergot alkaloids” such as ergotamine or dihydroergotamine used to treat migraines.
Noxafil može povećati količinu ovih lijekova u krvi, što može dovesti do vrlo ozbiljnih promjena srčanog ritma. svi lijekovi koji sadrže ergot alkaloide, kao što su ergotamin ili dihidroergotamin koji se primjenjuju za liječenje migrena.
Noxafil concentrate for solution for infusion is a clear, colourless to yellow liquid.
Noxafil koncentrat za otopinu za infuziju je bistra, bezbojna do žuta tekućina.
Noxafil concentrate for solution for infusion should not be given by bolus administration.
Noxafil koncentrat za otopinu za infuziju ne smije se primjenjivati kao bolus.
Noxafil is for single use.
Noxafil je namijenjen za jednokratnu uporabu.
Noxafil is used to treat adults (aged 18 years or over) with the following fungal diseases, when treatments with other antifungal medicines (amphotericin B, itraconazole or fluconazole) cannot be tolerated or have failed: invasive aspergillosis (fungal infection caused by Aspergillus),
Noxafil se koristi za liječenje odraslih osoba (u dobi od 18 godina ili starijih) sa sljedećim gljivičnim bolestima u slučaju kada bolesnici ne podnose druge terapije antifungicidima (amfotericinom B, itrakonazolom ili flukonazolom) ili kada iste nisu uspješne: invazivna aspergiloza (gljivična infekcija prouzročena gljivicama iz obitelji Aspergillus),
Noxafil must not be diluted with:
Noxafil se ne smije razrjeđivati s: